Combination of one of the premier cancer research centers with a strong company builder and Evotec's drug discovery expertise to create and support new companies focused on therapeutic breakthroughs for patients in the areas of oncology and infectious diseases Expands Evotec's academic ‘BRIDGE’ initiative under EVT INNOVATE Initial term of LAB591...

$ 6 M payment to access additional cell lines

Leveraging Evotec's phenotypic screening capabilities and compound libraries with an initial focus on solid tumours Upfront payment of $ 65 M, significant milestone payments and tiered royalties per programme

55% increase in Group revenues Strong underlying operational performance with new business mix after Aptuit acquisition “3X30” outlook for 2018 confirmed Webcast and conference call today at 02.00 pm CEST

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing time from nomination to regulatory submission

Hamburg, Germany, 02 May 2018:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its...